{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}],"units":"Participants"}],"description":"The calculation for Complete Response Rate is as follows: complete response \\[CR\\] / complete response with incomplete blood count recovery \\[CRi\\] / CRmarrow / partial response \\[PR\\] / hematologic improvement \\[HI\\]","groups":[{"description":"Decitabine is administered as a 1-hour intravenous (IV) infusion (IVI) daily days 1-5 at 20mg/m2; followed on day 8 by Alvocidib 20mg/m2 (30min bolus) and Alvocidib 20mg/m2 (4 hr IVI)","id":"OG000","title":"ALV-DEC: Cohort 1"},{"description":"Decitabine is administered as a 1-hour intravenous (IV) infusion (IVI) daily days 1-5 at 20mg/m2; followed on day 8 by Alvocidib 20mg/m2 (30min bolus) and Alvocidib 30mg/m2 (4 hr IVI)","id":"OG001","title":"ALV-DEC: Cohort 2"},{"description":"Decitabine is administered as a 1-hour intravenous (IV) infusion (IVI) daily days 1-5 at 20mg/m2; followed on day 8 by Alvocidib 20mg/m2 (30min bolus) and Alvocidib 45mg/m2 (4 hr IVI)","id":"OG002","title":"ALV-DEC: Cohort 3"},{"description":"Decitabine is administered as a 1-hour intravenous (IV) infusion (IVI) daily days 1-5 at 20mg/m2; followed on day 8 by Alvocidib 20mg/m2 (30min bolus) and Alvocidib 60mg/m2 (4 hr IVI)","id":"OG003","title":"ALV-DEC: Cohort 4"},{"description":"Azacitidine (AZA) administered on either a 7-day schedule or a 5-2-2 schedule (once daily for 5 days followed by 2 drug-free days with 2 more days of treatment) at 75mg/m2 per day subcutaneously or via IVI. Alvocidib (ALV) administered on day 10 at 75mg/m2 as a 30-60 minute IVI.","id":"OG004","title":"ALV-AZA: Cohort 5"},{"description":"Azacitidine (AZA) administered on either a 7-day schedule or a 5-2-2 schedule (once daily for 5 days followed by 2 drug-free days with 2 more days of treatment) at 75mg/m2 per day subcutaneously or via IVI. Alvocidib (ALV) administered on day 10 at 90mg/m2 as a 30-60 minute IVI.","id":"OG005","title":"ALV-AZA: Cohort 6"}],"populationDescription":"Sponsor's decision to terminate further development of the alvocidib program. Data collection and analysis were therefore not conducted as planned.","reportingStatus":"POSTED","timeFrame":"From the date of first treatment, every 8 weeks, for the first 6 cycles, for an average of 26 weeks","title":"Determination of the Complete Response Rate","type":"SECONDARY"}